About Centrexion Therapeutics
Centrexion Therapeutics is a private company based in Boston, Massachusetts. It has reported $178,477,026 raised in 11 offerings on Form D since March 2016.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Dec 28, 2023 | Jan 8, 2024 | $3,255,467of $12.8M target | 116 | $28,064 | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Nov 14, 2023 | Nov 27, 2023 | $2,300,000fully sold | 2 | $1.1M | Debt, Options, Securities on exerciseRule 506(b) | Form D ↗ |
| Jun 14, 2023 | Jun 29, 2023amended Jul 11, 2023 | $10,280,238of $30.0M target | 124 | $82,905 | Debt, Options, Securities on exerciseRule 506(b) | Form D/A ↗1 earlier filing |
| May 24, 2022 | Jun 8, 2022amended Aug 11, 2022 | $29,140,000fully sold | 47 | $620K | Debt, Options, Securities on exerciseRule 506(b) | Form D/A ↗2 earlier filings |
| Jan 12, 2021 | Jan 26, 2021 | $13,500,000fully sold | 17 | $794K | Debt, Securities on exerciseRule 506(b) | Form D ↗ |
| Dec 18, 2017 | Jan 2, 2018 | $69,566,532fully sold | 67 | $1.0M | EquityRule 506(b) | Form D ↗ |
| Apr 28, 2017 | May 23, 2017 | $5,285,000target not set | 40 | $132K | Options, Convertible NotesRule 506(b) | Form D ↗ |
| Dec 30, 2016 | Jan 5, 2017 | $16,564,789fully sold | 14 | $1.1M | Equity, Series C Convertible Preferred.Rule 506(b) | Form D ↗ |
| Jun 14, 2016 | Jun 21, 2016 | $11,163,500target not set | 61 | $183K | Convertible notes and associated warrantsRule 506(b) | Form D ↗ |
| Apr 8, 2016 | Apr 15, 2016 | $6,905,000target not set | 21 | $328K | Convertible notes and associated warrantsRule 506(b) | Form D ↗ |
| Mar 1, 2016 | Mar 14, 2016 | $10,516,500target not set | 25 | $420K | Convertible notes and associated warrantsRule 506(b) | Form D ↗ |
| Total, 11 offerings | $178,477,026 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Centrexion Therapeutics's Form D filed Jan 8, 2024.
Earlier filings also listed Sol Barer (director, last listed Aug 2022), Peter Wirth (director, last listed Aug 2022), J. Lopez, M.D. (director, last listed Aug 2022), Dezhi Kang, Ph.D. (director, last listed Aug 2022), Stella Xu (director, last listed Jan 2021), Sara Nayeem (director, last listed Jan 2021), James Campbell (executive officer and director, last listed Jan 2021) and Daniel Mendelson (director, last listed Jan 2021).